Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer. 

Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy.  

Now, researchers from Japan have evaluated the efficacy and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma.  

The findings revealed that this combination exhibited a manageable safety profile and may redefine treatment strategies, offering new hope for patients with recurrent thymic cancer. 

Thymic epithelial tumours are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma. Among these, thymic carcinoma is the more aggressive subtype, characterised by high invasiveness, metastatic potential, and poor prognosis. 

While platinum-based chemotherapy remains the current standard of care, its efficacy is limited. Immune checkpoint inhibitors have shown promise in pretreated cases, but durable and effective systemic therapies for chemotherapy-naïve patients remain a critical unmet need. 

The MARBLE Phase II study

A team of researchers, led by Associate Professor Takehito Shukuya from the Department of Respiratory Medicine, Juntendo University, Japan, conducted the MARBLE study to evaluate the combination of atezolizumab, an immune checkpoint inhibitor, with carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma.  

The findings of the study were published in Volume 26, Issue 3 of The Lancet Oncology. 

The multicentre, single-arm, Phase II clinical trial was conducted across 15 hospitals in Japan and enrolled 48 patients with histologically confirmed advanced or recurrent thymic carcinoma.  

During the induction phase, patients received a combination of atezolizumab, carboplatin, and paclitaxel every three weeks for up to six cycles. Those with non-progressive disease transitioned to a maintenance phase, receiving atezolizumab every three weeks for up to two years. 

With a median follow-up of 15.3 months, the combination therapy achieved an objective response rate of 56% and a median progression-free survival (PFS) of 9.6 months, outperforming historical chemotherapy outcomes. The disease control rate reached 98%, with 56% of patients achieving partial responses and 42% maintaining stable disease. 

Professor Shukuya said: “The combination of regimen delivers durable tumour responses and prolonged disease control with manageable safety, positioning it as a potential new standard of care. With these favourable results, approval for insurance coverage in Japan and globally, is anticipated.”

Diana Spencer, Senior Digital Content Editor, DDW